Market Research Logo

Varicose Ulcer - Pipeline Insight, 2019

Varicose Ulcer - Pipeline Insight, 2019 report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Varicose Ulcer pipeline landscape is provided which includes the disease overview and Varicose Ulcer treatment guidelines. The assessment part of the report embraces, in depth Varicose Ulcer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Varicose Ulcer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Varicose Ulcer Understanding
Venous ulcers (also known as venous stasis ulcers or nonhealing wounds) are open wounds commonly located on the ankle or calf, venous stasis ulcers are painful and red in color but may be covered with a yellow, fibrous tissue and an irregular border. Drainage and discharge are possible with venous stasis ulcers. This type of ulcer is common in patients with a history of leg swelling or varicose veins. They do not heal for weeks or months, and occasionally persist longer. A venous ulcer often feels itchy or burns, and the leg around it may be swollen. Other signs may include: A rash or dry skin, Brownish discoloration, a foul-smelling fluid oozing from the sore etc.

Varicose Ulcer Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Varicose Ulcer targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Varicose Ulcer pipeline report covers 12+ companies. Some of the key players include Rheacell (APZ 2), Factor Therapeutics (VF 001) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Varicose Ulcer Analytical Perspective by DelveInsight
• In-depth Varicose Ulcer Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
• Varicose Ulcer Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report
• The Varicose Ulcer report provides an overview of therapeutic pipeline activity for Varicose Ulcer across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of Varicose Ulcer therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
• Detailed Varicose Ulcer Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Varicose Ulcer
Reasons to Buy
• Establish a comprehensive understanding of the current pipeline scenario across Varicose Ulcer to formulate effective R&D strategies
• Assess challenges and opportunities that influence Varicose Ulcer R&D
• Develop strategic initiatives by understanding the focus areas of leading companies.
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Get in detail information of each product with updated information on each project along with key milestones
• Devise Varicose Ulcer in licensing and out licensing strategies by identifying prospective partners with progressing projects for Varicose Ulcer to enhance and expand business potential and scope
• Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs*Please Note:* The report will be delivered in 2 business days upon order confirmation.


1. Report Introduction
2. Varicose Ulcer (Venous ulcers venous stasis ulcers or non-healing wounds)
2.1. Varicose Ulcer Disease Overview
2.2. Varicose Ulcer History
2.3. Varicose Ulcer Symptoms
2.4. Varicose Ulcer Causes
2.5. Varicose Ulcer Pathophysiology
2.6. Varicose Ulcer Diagnosis
2.6.1. Diagnostic Guidelines
3. Varicose Ulcer Current Treatment Patterns
3.1. Treatment Guidelines
4. Varicose Ulcer- DelveInsight’s Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Varicose Ulcer companies collaborations, Licensing, Acquisition –Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Varicose Ulcer Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Varicose Ulcer Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA
5. Varicose Ulcer Pipeline Therapeutics
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products
6. Varicose Ulcer-Products Analysis
6.1. Product Profiles
6.1.1. APZ 2- Rheacell
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
6.1.2. VF 001- Factor Therapeutics
6.1.2.1. Product Description
6.1.2.1.1. Product Overview
6.1.2.1.2. Mechanism of Action
6.1.2.2. Research and Development
6.1.2.2.1. Clinical Studies
6.1.2.2.1.1. Detailed Study Description
6.1.2.2.1.2. Study Results
6.1.2.2.1.3. Clinical Trials: Tabular View
6.1.2.3. Product Development Activities
6.1.2.3.1. Tabulated Product Summary
6.1.2.3.1.1. General Description Table
To be continued in the report
7. Recent Technologies
8. Varicose Ulcer Key Companies
8.1. Glycotex
8.2. FirstString Research
8.3. Johnson & Johnson
8.4. Factor Therapeutics
8.5. CRC for Tissue Growth and Repair
8.6. GlaxoSmithKline
8.7. Intercytex
8.8. NB Therapeutics
8.9. Photopharmica
8.10. Healthpoint
8.11. ProMore Pharma
8.12. RHEACELL
9. Varicose Ulcer Key Products
9.1. TR 987
9.2. Granexin
9.3. Becaplermin gel
9.4. VF 001
9.5. PV 702
9.6. Repifermin
9.7. ICX-PRO
9.8. Nitric oxide topical
9.9. PPA 904
9.10. HP 802247
9.11. LL 37
9.12. APZ 2
10. Dormant and Discontinued Products
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. Varicose Ulcer- Unmet Needs
12. Varicose Ulcer- Future Perspectives
13. Appendix
14. Report Methodology
14.1. Secondary Research
14.2. Expert Panel Validation
Table 1. Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Varicose Ulcer Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products
Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Varicose Ulcer companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Varicose Ulcer Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook